NSE: NEULANDLAB · 26 October 2026
- Neuland Laboratories Ltd. (NEULANDLAB) traded higher during the session, up 0.72% at ₹19,000.00 compared to its previous close of ₹18,865.00. The stock moved within a day's range of ₹18,485.00 and ₹19,050.00 after opening lower at ₹18,485.00.
- Neuland Laboratories announced that the US FDA issued an Establishment Inspection Report (EIR) for the inspection conducted at its Unit 3 manufacturing facility in Sangareddy District from August 10 to August 14, 2026. The regulatory authority has formally concluded that this inspection is closed.
- Trading volume was 0.17 times the 20-day average daily volume.
Why is Neuland Laboratories share price rising on 26 October 2026?
Neuland Laboratories Ltd. (NEULANDLAB) traded higher during the session, up 0.72% at ₹19,000.00 compared to its previous close of ₹18,865.00. The stock moved within a day's range of ₹18,485.00 and ₹19,050.00 after opening lower at ₹18,485.00.
The broader market and sector showed modest positive momentum, with the Nifty rising 0.10% and the Nifty Pharma sector benchmark gaining 0.81%.
Recent company developments provide broader operational context rather than a direct trigger for today's price action. Notably, the US FDA concluded its inspection of the company's Unit 3 manufacturing facility as 'closed' following the issuance of an Establishment Inspection Report on October 14, 2026. Additionally, the company announced the commercial operation of its first peptide manufacturing module in September 2026, backed by a $30 million investment, to cater to rising customer demand across global markets.
7,946 shares traded by 26 October 2026 · 10:40 AM IST. This compares with a 20-day average daily volume of 48,114 shares (0.17 times). The five-day average daily volume was 42,476 shares. Separately, the NSE report for 23 October 2026 showed 25,786 shares delivered, representing 48.34% of that day’s traded volume. The same report recorded 22,618 trades.
The stock gained 0.72% in alignment with positive sectoral momentum in pharma, though trading volumes remained thin relative to the 20-day average volume of 0.17x. No single same-day catalyst was disclosed to directly drive the price move.
Latest Company Developments
Neuland Laboratories announced that the US FDA issued an Establishment Inspection Report (EIR) for the inspection conducted at its Unit 3 manufacturing facility in Sangareddy District from August 10 to August 14, 2026. The regulatory authority has formally concluded that this inspection is closed.
Closes out a key regulatory audit without lingering uncertainties, supporting compliance standing for the manufacturing unit.
Neuland accelerated its peptide manufacturing expansion by commencing operations at its first commercial module, featuring 7,000L of total reactor capacity following a $30 million investment. The company is also laying groundwork for subsequent modules to address growing customer demand in complex peptide APIs.
Expands high-value CDMO capabilities in fast-growing therapeutic areas like metabolic disorders and oncology.
The board approved a capital expenditure of ₹126 crores to acquire approximately 134 acres of land at Auro Industrial City in Kakinada, Andhra Pradesh, with a right of first refusal for an additional 66 contiguous acres. The land is earmarked to support the company's long-term manufacturing expansion plans.
Secures strategic physical footprint for future manufacturing scale-up beyond existing facilities.
a press release dated August 05, 2026, titled "Press Release on the Financial Results of the Company for the quarter ended June 30, 2026".
'We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility and would like to inform that the US FDA has issued an EIR against the inspection conducted from August 10, 2026 to August 14, 2026. The US FDA has concluded that this inspection is closed.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 12.45% on 30 September 2026. This compares with 12.66% on 30 June 2026, a change of -0.21 percentage points.
The filing reported 34 MF/UTI holders.
Research & Brokerage Views
Retained a 'Buy' rating following robust quarterly performance that exceeded prior estimates.
Maintained a positive stance highlighting strong institutional backing and growth visibility.
Historical Bulk / Block Deals
What to Watch Next
- Upcoming financial results for the quarter and half year ended September 30, 2026, scheduled for board review on November 3, 2026.
- Execution progress and client onboarding timelines for the newly operational peptide manufacturing module.
- Cash volume and delivery participation patterns compared to the 20-day average volume.
- Further updates regarding capital deployment on the newly acquired land parcel in Kakinada.
More Neuland Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Neuland Laboratories company news?
Neuland Laboratories announced that the US FDA issued an Establishment Inspection Report (EIR) for the inspection conducted at its Unit 3 manufacturing facility in Sangareddy District from August 10 to August 14, 2026. The regulatory authority has formally concluded that this inspection is closed.
How strong was Neuland Laboratories’s trading volume?
7,946 shares traded, 0.17 times the 20-day average daily volume. The price and volume data are dated 26 October 2026 · 10:40 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.